CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Cell therapy protocol 2Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (6)


Name (Synonyms) Correlation
drug98 BNT162a1 Wiki 1.00
drug99 BNT162b1 Wiki 1.00
drug180 Cell therapy protocol 1 Wiki 1.00
drug101 BNT162c2 Wiki 1.00
drug100 BNT162b2 Wiki 1.00
drug616 Placebo Wiki 0.10

Correlated MeSH Terms (3)


Name (Synonyms) Correlation
D055371 Acute Lung Injury NIH 0.16
D012127 Respiratory Distress Syndrome, Newborn NIH 0.15
D012128 Respiratory Distress Syndrome, Adult NIH 0.13

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Mesenchymal Stem Cell Therapy for Acute Respiratory Distress Syndrome in Coronavirus Infection: A Phase 2-3 Clinical Trial

Acute Respiratory Distress Syndrome (ARDS) is the major cause of death in the COVID-19 pandemic. In this trial, the safety and efficacy of Mesenchymal Stem Cells (MSC) for the treatment of ARDS in COVID-19 patients will be assessed.

NCT04366063 Covid-19 Biological: Cell therapy protocol 1 Biological: Cell therapy protocol 2
MeSH:Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Acute Lung Injury

Primary Outcomes

Description: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

Measure: Adverse events assessment

Time: From baseline to day 28

Description: Evaluation of Pneumonia Improvement

Measure: Blood oxygen saturation

Time: From baseline to day 14

Secondary Outcomes

Description: Number of days

Measure: Intensive care unit-free days

Time: Up to day 8

Description: Improvement of clinical symptoms including duration of fever, respiratory distress, pneumonia, cough, sneezing

Measure: Clinical symptoms

Time: From baseline to day 14

Description: increase in PaO2/FiO2 ratio from baseline to day 7

Measure: Respiratory efficacy

Time: From baseline to day 7

Description: Biochemical examination

Measure: Biomarkers concentrations in plasma

Time: At baseline, 7, 14, 28 days after the first intervention


No related HPO nodes (Using clinical trials)